Dsred Vsv Spike Protein

Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78637-1 100 µl
EUR 795
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices.

Human IgG antibody Laboratories manufactures the dsred vsv spike protein reagents distributed by Genprice. The Dsred Vsv Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Dsred products are available in stock. Specificity: Dsred Category: Vsv Group: Spike Protein

VSV-G-tag Antibody

100ul
EUR 399.6

VSV-G-tag Antibody

50ul
EUR 286.8

VSV-g Tag Antibody

100ul
EUR 399.6

VSV-g Tag Antibody

50ul
EUR 286.8

VSV- G tag Antibody

100 ug
EUR 525.6

VSV-G tag Antibody

100 ug
EUR 385.2

VSV-G-Tag Antibody

  • EUR 393.60
  • EUR 326.40
  • 100 ug
  • 50 ug

Spike Protein information

Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78640-1 100 µl
EUR 795
Description: The Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Delta B.1.617.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based Spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in B.1.617.2 Delta Variant:T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N

Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78640-2 500 µl x 2
EUR 3995
Description: The Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Delta B.1.617.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based Spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in B.1.617.2 Delta Variant:T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N

COVID-19 Spike Protein a.a. 1000-12000

00223-V-100ugvial 100 ug/vial
EUR 150
Description: COVID-19 Spike Protein a.a. 1000-12000

Recombinant SARS Spike gp C Protein

VAng-Lsx0072-inquire inquire Ask for price
Description: SARS Spike glycoprotein C, recombinant protein from E. coli.

Anti-MERSC-CoV Spike Protein antibody

STJ140102 150 µg
EUR 277.2
Description: Goat polyclonal to Spike protein of Middle East respiratory Syndrome coronavirus. Coronaviruses access host cells by membrane fusion, a process mediated by specific fusion or “spike” proteins on the virion, often activated by cellular proteases.

MERS-CoV Spike protein (aa 383-502) [Fc]

DAG-H10297 20µg
EUR 868.8

MERS-CoV Spike protein (aa 367-606) [Fc]

DAG-H10302 20µg
EUR 868.8

COVID-19 Spike Protein a.a. 800 to 1000

00222-V-100ugvial 100 ug/vial
EUR 150
Description: COVID-19 Spike Protein a.a. 800 to 1000

MERS-CoV Spike protein (aa 1-1297) [His]

DAG-H10300 20µg
EUR 868.8

MERS-CoV Spike Protein (aa 367-606) [His]

DAGB201 20 µg
EUR 868.8

MERS Spike S1 Recombinant protein

39-102 0.1 mg
EUR 556.8
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis.

Recombinant SARS Spike Protein (aa 1-1190) [His]

VAng-Lsx0063-inquire inquire Ask for price
Description: SARS Spike protein (aa 1-1190) [His], recombinant protein from HEK 293 cells.

COVID-19 Spike S1 protein a.a. 1 to 800

00226-V-100ugvial 100 ug/vial
EUR 150
Description: COVID-19 Spike S1 protein a.a. 1 to 800

MERS-CoV Spike protein S2 (aa 726-1296) [His]

DAG-H10296 20µg
EUR 868.8

MERS-CoV Spike protein S1 (aa 1-725) [His]

DAG-H10298 20µg
EUR 868.8

MERS-CoV Spike protein S1 (aa 1-725) [His]

DAG-H10301 20µg
EUR 868.8

SARS Spike RBD Recombinant Protein

10-211 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.